338 related articles for article (PubMed ID: 9259775)
81. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect.
Faham A; Altin JG
J Immunol; 2010 Aug; 185(3):1744-54. PubMed ID: 20610649
[TBL] [Abstract][Full Text] [Related]
82. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells.
Bellone M; Iezzi G; Martin-Fontecha A; Rivolta L; Manfredi AA; Protti MP; Freschi M; Dellabona P; Casorati G; Rugarli C
J Immunol; 1997 Jan; 158(2):783-9. PubMed ID: 8992995
[TBL] [Abstract][Full Text] [Related]
83. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
[TBL] [Abstract][Full Text] [Related]
84. The maturation of murine bone marrow-derived dendritic cells by tumor lysate uptake in vitro is not essential for cancer immunotherapy.
Woo SC; Kim GY; Lee CM; Moon DO; Kim HK; Lee TH; Moon YS; Park NC; Yoon MS; Lee KS; Park YM
Cancer Biol Ther; 2005 Dec; 4(12):1331-5. PubMed ID: 16322691
[TBL] [Abstract][Full Text] [Related]
85. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
Paglia P; Chiodoni C; Rodolfo M; Colombo MP
J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
[TBL] [Abstract][Full Text] [Related]
86. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
87. CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization.
Mazouz N; Ooms A; Moulin V; Van Meirvenne S; Uyttenhove C; Degiovanni G
Cancer Immun; 2002 Mar; 2():2. PubMed ID: 12747747
[TBL] [Abstract][Full Text] [Related]
88. Immunization with antigen-pulsed dendritic cells significantly improves the immune response to weak self-antigens.
Vargas P; Cortés C; Vargas L; Rosemblatt M; Bono MR
Immunobiology; 2006; 211(1-2):29-36. PubMed ID: 16446168
[TBL] [Abstract][Full Text] [Related]
89. Carbon-ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma.
Matsunaga A; Ueda Y; Yamada S; Harada Y; Shimada H; Hasegawa M; Tsujii H; Ochiai T; Yonemitsu Y
Cancer; 2010 Aug; 116(15):3740-8. PubMed ID: 20564091
[TBL] [Abstract][Full Text] [Related]
90. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge.
Hermans IF; Daish A; Moroni-Rawson P; Ronchese F
Cancer Immunol Immunother; 1997 Aug; 44(6):341-7. PubMed ID: 9298937
[TBL] [Abstract][Full Text] [Related]
91. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
92. T-cells for tumor therapy can be obtained from antigen-loaded sponge implants.
Chen W; Reese VA; Cheever MA
Cancer Res; 1994 Feb; 54(4):1065-70. PubMed ID: 8313363
[TBL] [Abstract][Full Text] [Related]
93. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
[TBL] [Abstract][Full Text] [Related]
94. Tumor vaccine composed of CpG ODN class C and irradiated tumor cells up-regulates the expression of genes characteristic of mature dendritic cells and of memory cells.
Cerkovnik P; Jezersek Novakovic B; Stegel V; Novakovic S
Int J Oncol; 2011 Jun; 38(6):1749-58. PubMed ID: 21573508
[TBL] [Abstract][Full Text] [Related]
95. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
[TBL] [Abstract][Full Text] [Related]
96. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
Dashti A; Ebrahimi M; Hadjati J; Memarnejadian A; Moazzeni SM
Cancer Lett; 2016 Apr; 374(1):175-185. PubMed ID: 26803056
[TBL] [Abstract][Full Text] [Related]
97. Escape mechanisms of melanoma from immune system by soluble melanoma antigen.
Takahashi K; Ono K; Hirabayashi Y; Taniguchi M
J Immunol; 1988 May; 140(9):3244-8. PubMed ID: 2452202
[TBL] [Abstract][Full Text] [Related]
98. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine.
Adam C; Mysliwietz J; Mocikat R
J Transl Med; 2007 Mar; 5():16. PubMed ID: 17359532
[TBL] [Abstract][Full Text] [Related]
99. Immunosensitization with a Bcl-2 small molecule inhibitor.
Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
[TBL] [Abstract][Full Text] [Related]
100. Synergistic combination of murine bone marrow-derived dendritic cells loaded ex vivo with whole tumor lysate and systemic chemotherapy mediates antitumor immune responses in vivo.
Salem ML; Nassef M; Gomaa S; Essa I
Biomed Pharmacother; 2017 Sep; 93():286-295. PubMed ID: 28648976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
